Sarcomas

Adolescent and young adult patients fall between the 2 age groups that clinicians are used to seeing, leading to gaps in care and poor outcomes.

The FDA has extended the Prescription Drug User Fee Act deadline for a new drug application (NDA) for avapritinib (Ayvakit) as a treatment for adult patients with fourth-line gastrointestinal stromal tumor (GIST). The deadline, which was initially February 14, 2020, has been extended by 3 months to May 14, 2020, according to BluePrint Medicines, the developer of avapritinib.

The presence of the proteins p16 and p21 has shown to be predictive of treatment response in patients with osteosarcoma, a disease that previously had no identified biomarkers to indicate whether or not patients would benefit from therapy, explained C. Parker Gibbs, MD.

The FDA has granted an accelerated approval to tazemetostat (Tazverik) for the treatment of adult and pediatric patients aged ≥16 years old with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.

The FDA has approved avapritinib (Ayvakit) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

The NDA for Blueprint Medicines' agent avapritinib will be split into two separate submissions for patients with GIST.

Clinical hypnosis offers a non-pharmacological approach to managing chronic pain after cancer treatment.

The FDA recommends that no new patients with advanced soft tissue sarcoma (STS) be treated with olaratumab (Lartruvo) plus doxorubicin, following the negative results of the phase III ANNOUNCE trial.

The FDA recommends that no new patients with advanced soft tissue sarcoma be treated with the combination of olaratumab (Lartruvo) plus doxorubicin.

The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) injection, a folate analog for 3 indications.

With antiretroviral drugs easing the burden of AIDS-defining cancers in HIV-positive patients, the most common cancers in this population are expected to shift to those associated with aging.

John E. Mullinax, M.D., discusses a chemotherapy strategy, isolated limb infusion, that may be able to save the limbs of some patients with sarcoma.

Trabectedin (Yondelis) chemotherapy was approved by the FDA for treatment of patients with specific metastatic soft tissue sarcomas-liposarcoma and leiomyosarcoma-who previously received chemotherapy that included an anthracycline.

A new study has shown that the risk of developing melanoma was more closely related to sun exposure in early life than in adulthood in young Caucasian women.

Singer and songwriter Charlie Lustman has become an inspirational voice for the over 12 million cancer survivors living in the United States